Evidence map›Paper›PMID 41586186›Full record

ArticleIranian journal of basic medical sciences2025

Effects of chitosan-titanium dioxide-Glucantime nanoassemblies on

Sanaz Tavakoli, Jaleh Varshosaz, Sedigheh Saberi, Mohammad Kazemi, Pardis Nematollahi, Nader Pestehchian

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Iranian journal of basic medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sanaz TavakoliDepartment of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Jaleh VarshosazDepartment of Pharmaceutics, School of Pharmacy and Novel Drug Delivery Systems Research Centre, Isfahan University of Medical Sciences, Isfahan, Iran.
Sedigheh SaberiDepartment of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Mohammad KazemiDepartment of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Pardis NematollahiDepartment of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Nader PestehchianDepartment of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Leishmaniasis, a neglected tropical disease, remains a public health concern. Meglumine antimonate (Glucantime®) is associated with high toxicity, prolonged treatment duration, and the emergence of drug resistance. This study aims to investigate a therapeutic strategy using chitosan-titanium dioxide-Glucantime (C-TiO₂-G) nanoassemblies comprising the natural polymer chitosan for drug loading, TiO₂ nanoparticles for enhanced cellular uptake, and Glucantime as the antileishmanial agent. Materials and Methods: Cytotoxicity was evaluated in the J774.A1 macrophage cell line to determine the IC50 values, and anti-leishmanial activity against Results: The nanoassemblies treatment exhibited reduced cytotoxicity with a significantly higher IC Conclusion: The findings highlight the potential of chitosan-titanium dioxide-Glucantime nanoassemblies as a promising therapeutic strategy against leishmaniasis.

Indexed as

Antileishmanial therapeutics Drug delivery systemsDrug resistance in – leishmaniasisLeishmania majorLeishmaniasis treatment – strategiesTitanium dioxide - nanoparticles

Identifiers

PMID41586186
PMCPMC12829697

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.